Cognition Therapeutics Inc (CGTX) Stock Price, Quote & News

Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mi...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 481 2210

Website: www.cogrx.com

Address:

2500 Westchester Ave., Purchase, United States

BPSJazz Jun. 25 at 4:36 AM

$CGTX - This is an interesting company. I'm buying.

0 · Reply

shmewdog Jun. 25 at 1:41 AM

$CGTX The market was speculating that we would get news of a partnership. This drop is way out of proportion. FDA is in alignment. Buying opportunity for long-term IMO, but probably a good idea to wait for some sort of recovery as who knows how low they can take it in the short term.

1 · Reply

Biopharma2021 Jun. 25 at 1:26 AM

$CGTX Bashers are out in force

1 · Reply

jiggs10 Jun. 24 at 11:36 PM

$CGTX looks to me like dilution n reverse split at some point. They laid an egg

5 · Reply

jiggs10 Jun. 24 at 11:34 PM

$CGTX This is going lower. They don't know how to run a company

0 · Reply

Ataifanboymentalhealthz Jun. 24 at 10:43 PM

$CGTX yah that’s the problem

0 · Reply

nottoday800 Jun. 24 at 10:35 PM

$CGTX this will go bacj under .65 ill get some then

0 · Reply

CraigGarrett Jun. 24 at 10:03 PM

$CGTX surely this is because they have diluted shares and sold a bunch today, right? There is no reason other than that for the stock to drop this much in a single day. The investor relations for this company had better tell us what the hell is going on. I am a long-term investor and I am pissed.

2 · Reply

Tyler66 Jun. 24 at 9:41 PM

$CGTX somebody please Take The hatchet out of Back ghezzzz bloody Wednesday, see this is why you have to look at it every day I think my heart just fell on my stomach

0 · Reply

Aimforsuccess Jun. 24 at 9:06 PM

$CGTX Fantastic news in my opinion and the market makers take it down to let institutions buy, in my opinion. A registration trial set with plenty of time to choose a partner or acquirer. Don’t ever forget our CEO’s record on sell outs of companies where she has worked.

0 · Reply

Cognition Therapeutics gets FDA feedback on zervimesine study

Jun 24, 2026, 7:30 AM EDT - 20 hours ago

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

Jun 17, 2026, 9:00 AM EDT - 7 days ago

Cognition Therapeutics Transcript: AGM 2026

2026-06-16T11:45:59.000Z - 8 days ago

Cognition Therapeutics gets notice of allowance from USPTO for zervimesine

Jun 16, 2026, 7:30 AM EDT - 8 days ago

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Jun 4, 2026, 1:25 PM EDT - 20 days ago

Cognition Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 7:00 AM EDT - 20 days ago

Cognition Therapeutics Slides: Investor presentation

Jun 1, 2026, 7:30 AM EDT - 23 days ago

Cognition Therapeutics Participating in Upcoming Investor Conferences

2026-05-21T11:48:47.000Z - 4 weeks ago

Cognition Therapeutics conducts zervimesine meeting with FDA

May 21, 2026, 7:30 AM EDT - 4 weeks ago

Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis

May 14, 2026, 7:30 AM EDT - 5 weeks ago

Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

2026-05-07T23:09:07.000Z - 6 weeks ago

Cognition Therapeutics reports Q1 EPS (5c), consensus (7c)

May 7, 2026, 4:15 PM EDT - 6 weeks ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

May 7, 2026, 4:00 PM EDT - 6 weeks ago

Cognition Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 6 weeks ago

Cognition Therapeutics Quarterly report: Q1 2026

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Cognition Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Cognition Therapeutics Proxy statement: Proxy filing

Apr 13, 2026, 3:00 PM EDT - 2 months ago

Cognition Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 7:30 AM EDT - 2 months ago

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

Mar 31, 2026, 4:30 PM EDT - 3 months ago

Cognition Therapeutics CEO Issues Letter to Shareholders

Mar 26, 2026, 8:30 AM EDT - 3 months ago

Cognition Therapeutics Earnings Call Transcript: Q4 2025

Mar 26, 2026, 8:30 AM EDT - 3 months ago

Cognition Therapeutics Earnings release: Q4 2025

Mar 26, 2026, 8:30 AM EDT - 3 months ago

Cognition Therapeutics Annual report: Q4 2025

Mar 26, 2026, 8:00 AM EDT - 3 months ago

Cognition Therapeutics Slides: Corporate presentation

Mar 26, 2026, 7:30 AM EDT - 3 months ago

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

2026-03-17T11:45:37.000Z - 3 months ago

Cognition Therapeutics’ zervimesine shows eficacy in dementia trial

Mar 17, 2026, 7:30 AM EDT - 3 months ago

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

2026-03-02T12:42:07.000Z - 4 months ago

Cognition Therapeutics announces plans to advance development of zervimesine

Mar 2, 2026, 7:30 AM EST - 4 months ago

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

2026-02-05T12:35:13.000Z - 4 months ago

Cognition Therapeutics extends duration of EAP for zervimesine

Feb 5, 2026, 7:30 AM EST - 4 months ago

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

2026-01-27T12:36:53.000Z - 5 months ago

Cognition Therapeutics completes Type C meeting with FDA for zervimesine

Jan 27, 2026, 7:30 AM EST - 5 months ago

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

2026-01-06T12:41:42.000Z - 6 months ago

Cognition publishes Phase 2 results on Zervimesine

Jan 6, 2026, 7:30 AM EST - 6 months ago

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies

2025-12-18T21:15:25.000Z - 6 months ago

Cognition Therapeutics files $300M mixed securities shelf

Dec 18, 2025, 7:00 AM EST - 6 months ago

Cognition Therapeutics Registration statement: Registration Filing

Dec 3, 2025, 4:30 PM EST - 7 months ago

Cognition Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-03T12:35:14.000Z - 7 months ago

Cognition reaches full enrollment in expanded access program for CT1812

2025-12-01T12:40:30.000Z - 7 months ago

Cognition Therapeutics presents Phase 3 plan for zervimesine in Alzheimer’s

Dec 1, 2025, 7:30 AM EST - 7 months ago

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference

2025-11-21T13:05:09.000Z - 7 months ago

Cognition Therapeutics price target raisd to $3 from $2 at B. Riley

Nov 20, 2025, 4:01 PM EST - 7 months ago

Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

2025-11-13T12:40:48.000Z - 7 months ago

Cognition Therapeutics completes enrollment in Phase 2 study of Zervimesine

Nov 13, 2025, 7:36 AM EST - 7 months ago

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease

2025-11-06T12:41:38.000Z - 8 months ago

Cognition Therapeutics reports Q3 EPS (6c), consensus (9c)

Nov 6, 2025, 7:30 AM EST - 8 months ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

Nov 6, 2025, 7:30 AM EST - 8 months ago

Cognition Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:30 AM EST - 8 months ago

Cognition Therapeutics Earnings release: Q3 2025

2025-09-03T11:35:11.000Z - 10 months ago

Cognition Therapeutics announces Phase 2 ‘START’ study reached 75% enrollment

Sep 3, 2025, 7:30 AM EDT - 10 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

Sep 2, 2025, 4:00 PM EDT - 10 months ago

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

2025-08-28T03:45:19.000Z - 10 months ago

Cognition Therapeutics announces $30M registered direct offering of common stock

Aug 27, 2025, 8:53 PM EDT - 10 months ago

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

2025-08-26T20:05:36.000Z - 10 months ago

Cognition Therapeutics regains compliance with Nasdaq

Aug 26, 2025, 4:00 PM EDT - 10 months ago

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

2025-08-12T21:05:20.000Z - 11 months ago

Cognition Therapeutics confirms aligment with FDA on path for zervimesine

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease

2025-08-07T20:10:27.000Z - 11 months ago

Cognition Therapeutics reports Q2 EPS (11c), consensus (10c)

Aug 7, 2025, 4:00 PM EDT - 11 months ago

Cognition Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 11 months ago

Cognition Therapeutics Quarterly report: Q2 2025

Jul 29, 2025, 7:30 AM EDT - 11 months ago

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

Jul 21, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease

Jul 16, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

Jul 10, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

Jul 1, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target

Jun 25, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)

Jun 3, 2025, 7:30 AM EDT - 1 year ago

Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

May 28, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

May 9, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

May 7, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

May 7, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Quarterly report: Q1 2025

May 7, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Cognition Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Cognition Therapeutics Proxy statement: Proxy Filing

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Cognition Therapeutics Earnings Call Transcript: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Cognition Therapeutics Earnings release: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Cognition Therapeutics Annual report: Q4 2024

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Cognition Therapeutics Transcript: Life Sciences Investor Forum

Mar 12, 2025, 4:05 PM EDT - 1 year ago

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

Mar 10, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

Feb 27, 2025, 7:30 AM EST - 1 year ago

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Feb 25, 2025, 7:30 AM EST - 1 year ago

Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

Jan 30, 2025, 7:30 AM EST - 1 year ago

Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Jan 8, 2025, 4:14 PM EST - 1 year ago

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

Dec 18, 2024, 8:00 AM EST - 1 year ago

Cognition Therapeutics Transcript: Study Result

Dec 18, 2024, 8:00 AM EST - 1 year ago

Cognition Therapeutics Press release: Study Result

Dec 18, 2024, 7:22 AM EST - 1 year ago

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Nov 26, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Nov 25, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population

Nov 14, 2024, 11:00 AM EST - 1 year ago

Cognition Therapeutics Transcript: Life Sciences Investor Forum

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Oct 31, 2024, 4:15 PM EDT - 1 year ago

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

BPSJazz Jun. 25 at 4:36 AM

$CGTX - This is an interesting company. I'm buying.

0 · Reply

shmewdog Jun. 25 at 1:41 AM

1 · Reply

Biopharma2021 Jun. 25 at 1:26 AM

$CGTX Bashers are out in force

1 · Reply

jiggs10 Jun. 24 at 11:36 PM

$CGTX looks to me like dilution n reverse split at some point. They laid an egg

5 · Reply

jiggs10 Jun. 24 at 11:34 PM

$CGTX This is going lower. They don't know how to run a company

0 · Reply

Ataifanboymentalhealthz Jun. 24 at 10:43 PM

$CGTX yah that’s the problem

0 · Reply

nottoday800 Jun. 24 at 10:35 PM

$CGTX this will go bacj under .65 ill get some then

0 · Reply

CraigGarrett Jun. 24 at 10:03 PM

2 · Reply

Tyler66 Jun. 24 at 9:41 PM

$CGTX somebody please Take The hatchet out of Back ghezzzz bloody Wednesday, see this is why you have to look at it every day I think my heart just fell on my stomach

0 · Reply

Aimforsuccess Jun. 24 at 9:06 PM

0 · Reply

Vinnie77 Jun. 24 at 8:57 PM

$CGTX disappointing reaction today, but a chance to buy some at low prices so I’m not that bothered. I have time to see this come to the appropriate levels

1 · Reply

mcclayjd40 Jun. 24 at 8:51 PM

$CGTX I suppose I’m deranged but I think something unforeseen is coming in the near future and it’s going to be very positive for this company. Just a gut feeling. We’ ll see.

1 · Reply

History101 Jun. 24 at 8:22 PM

$CGTX well that sucked

1 · Reply

Tech2026 Jun. 24 at 8:01 PM

$CGTX Not good, MM are in control. Will ride this storm!!

1 · Reply

Goodhealth Jun. 24 at 7:44 PM

$CGTX My take on the current situation is that Cognition is already in negotiations with potential partners. The company's negotiating potion is better with a long time horizon that they can adhere to if they do not get an agreement with one or more partners. This also shows potential partners that Cognition is not in a panic and has several options... Just my perception of the situation.

4 · Reply

Biopharma2021 Jun. 24 at 7:41 PM

$CGTX criminal cartel market makers manipulating the price

0 · Reply

Johnnie_Parlay Jun. 24 at 7:22 PM

$CGTX cautiously

0 · Reply

Marshallmathers1 Jun. 24 at 7:20 PM

$CGTX 40% drop seems excessive. Buying more

0 · Reply

Marshallmathers1 Jun. 24 at 7:19 PM

$CGTX Jfc…☹️

0 · Reply

GibsonFlyingV Jun. 24 at 7:14 PM

$CGTX nothing has changed. And anyone with any idea of what’s going on is holding this until well into 2027. This isn’t a day flip for little Kyle and his supreme hat with his monster energy drink and his vape pen with four computer screens in front of him. This one is for real. The price action we saw last two weeks wasn’t meant to last.

0 · Reply

Al0 Jun. 24 at 7:06 PM

$CGTX what!! 🙈 happened!! 😳

1 · Reply

FitzCatalyst Jun. 24 at 7:06 PM

$CGTX sheesh

0 · Reply

Market Cap	150.36M
Revenue (ttm)	0.00
Net Income (ttm)	-23.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	11,838,001
Avg Vol	1,376,354
Day's Range	N/A - N/A
Shares Out	89.50M
Stochastic %K	6%
Beta	1.75
Analysts	Strong Sell
Price Target	$3.50